IKBKG; AMCBX1; FIP-3; FIP3; Fip3p; IKK-gamma; IP; IP1; IP2; IPD2; NEMO; IKK gamma

For Research Use Only. Not for use in diagnostic procedures.

IgG

Rabbit

Affinity purification

Store at-20 degree C or-80 degree C. Avoid freeze/thaw cycles.

Small volumes of anti-IKBKG antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

The NF-kappaB/Rel transcription factors are present in the cytosol in an inactive state, complexed with the inhibitory IkappaB proteins (1-3). Most agents that activate NF-kappaB do so through a common pathway based on phosphorylation-induced, proteasome-mediated degradation of IkappaB (3-7). The key regulatory step in this pathway involves activation of a high molecular weight IkappaB kinase (IKK) complex whose catalysis is generally carried out by three tightly associated IKK subunits. IKKalpha and IKKbeta serve as the catalytic subunits of the kinase and IKK gamma serves as the regulatory subunit (8, 9). Activation of IKK depends upon phosphorylation of Ser177 and Ser181 in the activation loop of IKKbeta (Ser176 and Ser180 in IKKalpha), which causes conformational changes resulting in kinase activation (10-13).

Autophagy antibody; Cancer; Cardiovascular; Cell Biology; Epigenetics & Nuclear Signaling; Developmental Biologys; Immunology; Drug Discovery Products; Metabolism; Neuroscience; Signal Transduction; Stem Cells

Western Blot (WB), Immunohistochemistry (IHC)

WB: 1:500-1:2000
IHC: 1:50-1:200

Western blot analysis of extracts of various celllines, using IKBKG antibody.

48kDa

inhibitor of nuclear factor kappa B kinase subunit gamma

NF-kappa-B essential modulator

NF-kappa-B essential modulator

FIP3; NEMO; NEMO; IKKAP1; I-kappa-B kinase subunit gamma; IKK-gamma; IKKG; IkB kinase subunit gamma??[Similar Products]

This gene encodes the regulatory subunit of the inhibitor of kappaB kinase (IKK) complex, which activates NF-kappaB resulting in activation of genes involved in inflammation, immunity, cell survival, and other pathways. Mutations in this gene result in incontinentia pigmenti, hypohidrotic ectodermal dysplasia, and several other types of immunodeficiencies. A pseudogene highly similar to this locus is located in an adjacent region of the X chromosome. [provided by RefSeq, Mar 2016]

Regulatory subunit of the IKK core complex which phosphorylates inhibitors of NF-kappa-B thus leading to the dissociation of the inhibitor/NF-kappa-B complex and ultimately the degradation of the inhibitor. Its binding to scaffolding polyubiquitin seems to play a role in IKK activation by multiple signaling receptor pathways. However, the specific type of polyubiquitin recognized upon cell stimulation (either 'Lys-63'-linked or linear polyubiquitin) and its functional importance is reported conflictingly. Also considered to be a mediator for TAX activation of NF-kappa-B. Could be implicated in NF-kappa-B-mediated protection from cytokine toxicity. Essential for viral activation of IRF3. Involved in TLR3- and IFIH1-mediated antiviral innate response; this function requires 'Lys-27'-linked polyubiquitination.

1. Baeuerle, P.A. and Baltimore, D. (1988) Science 242, 540-6. 2. Beg, A.A. and Baldwin, A.S. (1993) Genes Dev 7, 2064-70. 3. Finco, T.S. et al. (1994) Proc Natl Acad Sci USA 91, 11884-8. 4. Brown, K. et al. (1995) Science 267, 1485-8. 5. Brockman, J.A. et al. (1995) Mol Cell Biol 15, 2809-18. 6. Traenckner, E.B. et al. (1995) EMBO J 14, 2876-83. 7. Chen, Z.J. et al. (1996) Cell 84, 853-62. 8. Zandi, E. et al. (1997) Cell 91, 243-52. 9. Karin, M. (1999) Oncogene 18, 6867-74. 10. DiDonato, J.A. et al. (1997) Nature 388, 548-54. 11. Mercurio, F. et al. (1997) Science 278, 860-6. 12. Johnson, L.N. et al. (1996) Cell 85, 149-58. 13. Delhase, M. et al. (1999) Science 284, 309-13.

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.